{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SSc&page=2",
    "query": {
      "condition": "SSc",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SSc&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T09:50:02.744Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05878717",
      "title": "A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Systemic Sclerosis Associated Interstitial Lung Disease",
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2023-09-13",
      "completion_date": "2029-07-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05878717"
    },
    {
      "nct_id": "NCT04797286",
      "title": "Sildenafil for Early Pulmonary Vascular Disease in Scleroderma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma",
        "Mildly Elevated Pulmonary Pressures"
      ],
      "interventions": [
        {
          "name": "Sildenafil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-09-20",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 2,
      "location_summary": "New Orleans, Louisiana • Baltimore, Maryland",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04797286"
    },
    {
      "nct_id": "NCT06843239",
      "title": "Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis (SSc)",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Tibulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Zura Bio Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2025-02-06",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06843239"
    },
    {
      "nct_id": "NCT01776398",
      "title": "Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Smoking",
        "Smoking Cessation",
        "Idiopathic Pulmonary Fibrosis (IPF)",
        "Rheumatoid Arthritis-Associated Interstitial Lung Disease",
        "Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2012-08-29",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01776398"
    },
    {
      "nct_id": "NCT02228850",
      "title": "Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Alprostadil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 35,
      "start_date": "2014-11",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 4,
      "location_summary": "Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228850"
    },
    {
      "nct_id": "NCT04915950",
      "title": "A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Temanogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-11-03",
      "completion_date": "2022-09-02",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04915950"
    },
    {
      "nct_id": "NCT02745145",
      "title": "Abituzumab in SSc-ILD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis-associated Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Abituzumab 1500 mg",
          "type": "DRUG"
        },
        {
          "name": "Abituzumab 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-05-31",
      "completion_date": "2018-05-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-18",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02745145"
    },
    {
      "nct_id": "NCT06375993",
      "title": "A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Autoimmune Diseases",
        "Systemic Sclerosis (SSc)",
        "Systemic Lupus Erythematosus (SLE)",
        "ANCA-Associated Vasculitis (AAV)",
        "Idiopathic Inflammatory Myopathies",
        "Stiff Person Syndrome"
      ],
      "interventions": [
        {
          "name": "ADI-001",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adicet Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 180,
      "start_date": "2024-11-10",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 2,
      "location_summary": "Redwood City, California • Buffalo, New York",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06375993"
    },
    {
      "nct_id": "NCT06991114",
      "title": "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Rheumatoid Arthritis (RA)",
        "Idiopathic Inflammatory Myopathies (IIMs)",
        "Systemic Sclerosis (SSc)",
        "Rheumatoid Arthritis (RA",
        "IIM",
        "Myositis",
        "Scleroderma",
        "Sjogren Syndrome",
        "Sjogrens Disease"
      ],
      "interventions": [
        {
          "name": "Allogeneic NK Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artiva Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-07-09",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 31,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06991114"
    },
    {
      "nct_id": "NCT05000216",
      "title": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis (RA)",
        "Systemic Lupus Erythematosus (SLE)",
        "Pemphigus Vulgaris",
        "Multiple Sclerosis (MS)",
        "Systemic Sclerosis (SSc)",
        "Pediatric SLE",
        "Juvenile Idiopathic Arthritis (JIA)",
        "Juvenile Dermatomyositis (JDM)",
        "Pediatric-Onset Multiple Sclerosis (POMS)"
      ],
      "interventions": [
        {
          "name": "Moderna mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.COV2.S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Continue IS (MMF or MPA)",
          "type": "DRUG"
        },
        {
          "name": "Continue IS (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Continue IS (B cell depletion therapy)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent [B.1.351] CoV2 preS dTM-AS03",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Withhold IS (MMF or MPA)",
          "type": "DRUG"
        },
        {
          "name": "Withhold IS (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Withhold IS (B cell depletion therapy)",
          "type": "DRUG"
        },
        {
          "name": "Moderna mRNA-1273, Bivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2, Bivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-08-13",
      "completion_date": "2024-03-28",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-07-24T09:50:02.744Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05000216"
    }
  ]
}